Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Whi-P131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | RET | P07949 | 6/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 5/20 | 0.97 |
| ▸ | KIF5B | P33176 | 4/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Whi-P131 SCHEMBL29295 | 1.00 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| Whi-P131 SCHEMBL6068752 | 0.99 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL20792806 | 0.93 | EGFR (0.87) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5472599 | 0.87 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL3533221 | 0.87 | EGFR (0.80) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5473778 | 0.87 | EGFR (0.80) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5467825 | 0.87 | EGFR (1.00) | EGFRKDRRETJAK3GAK | |
| SCHEMBL4477758 | 0.86 | EGFR (0.77) | EGFRKDRRETJAK3GAK | |
| SCHEMBL22299727 | 0.86 | EGFR (0.76) | EGFRKDRRETJAK3GAK | |
| SCHEMBL5477771 | 0.86 | KDR (1.00) | EGFRKDRRETJAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336828-B | Quinazoline derivative and preparation method and application thereof | 雅安职业技术学院 | 2022-04-26 | — | — | CN | claimed |
| CN-118267470-A | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-110650976-B | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115003303-B | PRMT5 inhibitors | 默沙东公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023250140-A1 | STAT3 INHIBITOR TO TREAT SUBARACHNOID HEMORRHAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4291565-A1 | SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-115087638-B | PRMT5 inhibitors | 默沙东公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-109890846-B | anti-CD 27 antibodies | 默沙东有限责任公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-108676800-B | RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115087638-A | PRMT5 inhibitor | 默沙东公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4051712-A1 | DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER | Merck Sharp & Dohme LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-115003303-A | PRMT5 inhibitor | 默沙东公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022173460-A1 | SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114761432-A | Dosing regimen of anti-CD 27 antibodies for treatment of cancer | 默沙东公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4003523-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | Merck Sharp & Dohme Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-109336828-B | Quinazoline derivative and preparation method and application thereof | 雅安职业技术学院 | 2022-04-26 | — | — | CN | disclosed |
| CN-109336828-B | Quinazoline derivative and preparation method and application thereof | 雅安职业技术学院 | 2022-04-26 | — | — | CN | disclosed |
| CN-110172056-B | Aminopyrimidine derivatives | 诺华股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |